DE651434C - Method of preventing denaturation of protein medicinal products dissolved in water - Google Patents
Method of preventing denaturation of protein medicinal products dissolved in waterInfo
- Publication number
- DE651434C DE651434C DEI47557D DEI0047557D DE651434C DE 651434 C DE651434 C DE 651434C DE I47557 D DEI47557 D DE I47557D DE I0047557 D DEI0047557 D DE I0047557D DE 651434 C DE651434 C DE 651434C
- Authority
- DE
- Germany
- Prior art keywords
- protein
- water
- medicinal products
- products dissolved
- preventing denaturation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 102000004169 proteins and genes Human genes 0.000 title claims description 11
- 108090000623 proteins and genes Proteins 0.000 title claims description 11
- 238000004925 denaturation Methods 0.000 title claims description 6
- 230000036425 denaturation Effects 0.000 title claims description 6
- 238000000034 method Methods 0.000 title claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims description 5
- 229940126601 medicinal product Drugs 0.000 title claims 2
- 239000007857 degradation product Substances 0.000 claims description 3
- 230000017854 proteolysis Effects 0.000 claims description 3
- 239000000243 solution Substances 0.000 description 12
- 238000005189 flocculation Methods 0.000 description 4
- 230000016615 flocculation Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000002253 acid Substances 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000009843 Thyroglobulin Human genes 0.000 description 2
- 108010034949 Thyroglobulin Proteins 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229960002175 thyroglobulin Drugs 0.000 description 2
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000003165 hydrotropic effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- -1 protalbic acid Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
Verfahren zur Verhinderung der Denaturierung in Wasser gelöster eiweißhaltiger Heilmittel Bekanntlich zeigen eiweißhaltige Lösungen die Eigenschaft, . daß sie nicht dauernd klar bleiben, sondern zur Flockenbildung neigen, was auf Denaturierung des Eiweißes beruht. Dieser -Umstand macht sich besonders bei therapeutischen Präparaten störend bemerkbar.Process for preventing denaturation of proteinaceous substances dissolved in water Remedies It is well known that solutions containing protein show the property. that they do not stay clear all the time, but tend to form flakes, which indicates denaturation of protein is based. This circumstance is particularly evident with therapeutic preparations noticeably disturbing.
Es wurde nun gefunden, daß man die Denaturierung und damit die Flockung von eiweißhaltigen Lösungen aufheben oder weitgehend verhindern kann, indem man den eiweißhaltigen. Lösungen höhermolekulare Eiweißabbauprodukte, insbesondere Säuren, wie Protalbinsäure, Lysalbinsäure usw., zugibt. Insbesondere sind die Salze dieser Eiweißabbauprodukte, besonders die Alkalisalze, für das Verfahren geeignet. Man führt das Verfahren zweckmäßig so aus, daß man die erwähnten Stoffe den fertigen Lösungen zugibt. Mit gleichem Erfolge können die die Flockung verhindernden Stoffe auch in einer beliebigen Stufe des Fabrikationsproz es,ses der eiweißhaltigen Lösung zugesetzt werden.It has now been found that the denaturation and thus the flocculation of protein-containing solutions can be eliminated or largely prevented by the protein-rich. Solutions of high molecular weight protein degradation products, especially acids, such as protalbic acid, lysalbic acid, etc., adds. In particular, the salts are these Protein breakdown products, especially the alkali salts, are suitable for the process. Man expediently carries out the process in such a way that the substances mentioned are finished Admits solutions. The substances preventing flocculation can be equally successful also in any stage of the manufacturing process of the protein-containing solution can be added.
Es ist zwar bekannt, daß höhermolekuilare Eiweißabbauprodukte die Eigenschaften von Schutzkolloiden besitzen und beispielsweise die Fähigkeit haben, Sole von Metallkolloiden vor der Ausflockung zu schützen. Weiterhin ist es bekannt, in Wasser unlösliche oder schwer lösliche Eiweißverbindungen durch den Zusatz hydrotropisch wirkender Körper in wässerige Lösungen zu überführen. Die Möglichkeit, die Denaturierung von in wässeriger Lösung befindlichem Eiweiß durch den Zusatz von höhermolekularen Eiweißabbauprodukten zu verhindern, ist demgegenüber jedoch neu und überraschend. Beispiele i. Eine i %ige Thyreoglobulinlösung wird nach dem Zusatz eines Sterilisierungsmittels. mit i 0,'o protalbinsaurem Natrium unter Umrühren versetzt. Die Lösung zeigt nach dem Filtrieren keine Flockenbildung mehr.It is known that protein degradation products of higher molecular weight are the Have the properties of protective colloids and, for example, have the ability To protect brine from metal colloids from flocculation. It is also known Protein compounds that are insoluble or sparingly soluble in water due to the addition of hydrotropic to transfer the acting body into aqueous solutions. The possibility of denaturation of protein in aqueous solution through the addition of higher molecular weight However, preventing protein breakdown products is new and surprising. Examples i. A i% thyroglobulin solution is after the addition of a sterilizing agent. with i 0, 'o sodium protalbinate while stirring. The solution shows no more flocculation after filtering.
2. Eine fraktionierte Thyreoglobulinlösung wird auf die gewünschte Konzentration eingestellt und mit so viel protalbinsaurem Natrium versetzt, daß die Lösung i 0 o0 davon enthält. Die Lösung wird nunmehr mit Trikresol sterilisiert und durch Seitzfilter geklärt.2. A fractionated thyroglobulin solution is added to the desired Concentration adjusted and treated with so much protalbinate sodium that the solution contains i 0 o0 thereof. The solution is now sterilized with tricresol and clarified by Seitz filters.
3. Trockenpulver von Inselhormon wird nach dem Ergebnis der Standardisierung mit Alkalialbuminat vermischt und die Substanz allmählich in der berechneten Menge sauren Wassers aufgelöst, so daß eine an Alkali= albumin.at r°/QOige Lösung entsteht. Nach denn'-Filtrieren erhält man eine beständige, keine' Flocken bildende Lösung. ' _3. Dry powder of islet hormone is made according to the result of standardization with Alkali albuminate mixed and the substance gradually in the calculated amount of acidic water, so that an alkali = albumin.at r ° / QOige Solution emerges. After filtering, a consistent, no 'flake is obtained forming solution. '_
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DEI47557D DE651434C (en) | 1933-07-09 | 1933-07-09 | Method of preventing denaturation of protein medicinal products dissolved in water |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DEI47557D DE651434C (en) | 1933-07-09 | 1933-07-09 | Method of preventing denaturation of protein medicinal products dissolved in water |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE651434C true DE651434C (en) | 1937-10-15 |
Family
ID=7192024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DEI47557D Expired DE651434C (en) | 1933-07-09 | 1933-07-09 | Method of preventing denaturation of protein medicinal products dissolved in water |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE651434C (en) |
-
1933
- 1933-07-09 DE DEI47557D patent/DE651434C/en not_active Expired
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2240782A1 (en) | METHOD FOR PRODUCING AN IRON SACCHARIDE COMPLEX | |
| DE2433209A1 (en) | HEAT-STABLE PLASMA PROTEIN SOLUTIONS, PROCESS FOR THEIR PRODUCTION AND MEDICINAL PREPARATIONS | |
| Strack et al. | Die Darstellung von L-Carnitin und seiner Isomeren | |
| DE651434C (en) | Method of preventing denaturation of protein medicinal products dissolved in water | |
| DE642313C (en) | Means for keeping cut flowers fresh | |
| AT144185B (en) | Process for the preparation of non-flocculent solutions of proteinaceous medicinal products. | |
| DE960579C (en) | Process for the production of a heat-sterilizable adrenocorticotropin preparation | |
| CH178361A (en) | Process for the preparation of non-flocculent solutions of therapeutic products containing proteins. | |
| DE712791C (en) | Process for the preparation of solutions of the blood sugar lowering pancreatic hormone | |
| DE750119C (en) | Process for the production of protein substances from muscle fibers of animal origin | |
| DE505062C (en) | Process for the production of drugs for organ or. tissue-specific treatment of diseases of the human and animal body | |
| DE940133C (en) | Process for obtaining highly effective organ extracts | |
| AT157575B (en) | Process for the production of undecomposed, sterilizable drug solutions from the double compound theophylline-piperazine. | |
| DE464674C (en) | Process for the preparation of products containing cholesterol which are colloidally soluble in an alkaline medium | |
| AT146967B (en) | Process for the production of heavy metal compounds of the porphine series. | |
| DE629841C (en) | Process for the preparation of an aqueous quinine solution for injection purposes | |
| AT127981B (en) | Process for the production of an irritant which promotes and regulates the central activities. | |
| DE417973C (en) | Process for the production of colloidal metal solutions | |
| DE874061C (en) | Process for the production of a blood-coagulant substance from the lungs | |
| AT129490B (en) | Process for obtaining the anterior pituitary lobe hormone, which is characterized by its development-promoting and stimulating effect on the gonads, in a pure state. | |
| DE519320C (en) | Process for the production of sulphobasic mercury compounds | |
| AT124884B (en) | Process for the production of hormone preparations. | |
| DE531846C (en) | Process for the production of physiologically active copper-arsenic compounds | |
| DE680339C (en) | Process for the production of plant extracts that remain clear | |
| DE662835C (en) | Process for the preparation of water-soluble laxatives |